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INTRODUCTION
In sporadic colorectal cancer, various genetic changes, in-
cluding adenomatous polyposis coli (APC), mismatch repair
(MMR), Wnt-mediated, BRAF-mediated, cell biology-asso-
ciated, and p53 alterations are concurrently observed (1). These
mutations are interconnected to generate diverse pathways
of colorectal tumorigenesis. 
Activation of the Wnt pathway through mutation of APC
triggers familial adenomatous polyposis coli (FAP) syndrome,
and somatic mutations of APC are frequently observed in the
majority of sporadic colorectal cancers (2). Inactivating muta-
tions of APC stabilize b-catenin, which is translocated into
the nucleus, leading to transcriptional upregulation of onco-
genes, such as c-myc and cyclin D1, and promotion of tumori-
genesis. b-catenin, the key component of the canonical Wnt
pathway, is regulated by a multiprotein complex consisting
of APC, Axin, and GSK-3b.
MMR defects occur due to gene inactivation and hMLH1
promoter methylation, frequently leading to microsatellite
instability (MSI). RAF mutations may additionally contribute
to colorectal carcinogenesis by upregulating anti-apoptotic
properties through the RAS/RAF/ERK pathway (3). The RAF
V600E hotspot mutation, occurring in approximately 10%
of colorectal cancers, is strongly associated with the microsatel-
lite instability phenotype (MSI+) (4). More specifically, RAF
mutations are found specifically in MSI+ sporadic tumors that
result from aberrant hMLH1 promoter methylation, but not
germline mutations. An earlier investigation showed that APC
or p53 mutations are more frequent in microsatellite stable
(MSS) than MSI+ tumors, indicating a significant negative
association between these alterations and microsatellite insta-
bility (5). On the other hand, nuclear b-catenin expression is
more common in MLH1-expressing sporadic colorectal can-
cers, associated with tumor progression in these tumors (6). 
Structural changes in extracellular matrix (ECM) proteins
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Growth and Invasion of Sporadic Colorectal Adenocarcinomas in Terms
of Genetic Change
Integrative genetic changes were examined in relation to tumor growth and progres-
sion of sporadic colorectal cancers. Ninety-two sporadic colorectal cancer patients
and 12 human colorectal cancer cell lines were evaluated. Genetic changes in rep-
resentative steps of colorectal tumorigenesis were determined. Biological charac-
teristics, i.e., clinicopathologic parameters, expression of invasion-associated mole-
cules, and in vitro invasion and migration, in association with these changes were
further analyzed. Adenomatous polyposis coli (APC) and/or Wnt-activated alterations
occurred in 66% patients, whereas mismatch repair (MMR) defects and/or RAF-
mediated alterations were identified in 47% patients. The crossover rate between
these two alterations was 26%. Differential mRNA expression of ARK5 was close-
ly associated with that of MMP2, MMP9, and S100A4 (P≤0.044-0.001). Additional-
ly, enhanced ARK5 mRNA expression was more frequent in tumors displaying
RAF-mediated alterations and crossover pathways (P=0.01 and 0.03, respective-
ly). Upregulation of CEA mRNA was more common in the advanced stages (P=
0.034), while VEGF expression was greater in poorly differentiated or mucinous
tumors (P=0.042). The high expressions of MMP2 and MMP9 were closely asso-
ciated with invasion and migration of colorectal tumors and cell lines. Our results
conclusively show that specific pathways of colorectal tumorigenesis are closely
associated with characteristic tumor growth and invasion.
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accomplished by complex control of the expression and activ-
ities of matrix metalloproteinases (MMPs) (7). Overexpres-
sion of MMPs leads to degradation of ECM, an essential step
for tumor invasion and metastasis (8). Particular groups of
MMPs, i.e., gelatinases A and B, also known as 72 and 92
kDa type IV collagenase or MMP-2 and MMP-9 respective-
ly, are of particular interest with respect to their roles in the
development and progression of colorectal cancer (9). The
metastatic capacity of colorectal cancer cells is closely associ-
ated with enhanced MMP production by the malignant cell
type. Alternatively, angiogenesis controlled by angiogenic
factors, such as the vascular endothelial growth factor (VEGF)
family of cytokines, is critical in tumor growth and metas-
tasis (10). VEGF-A and VEGF-B participate in tumor devel-
opment during adenoma formation, while VEGF-C functions
in the advanced stages of colorectal cancer (11). 
ARK5, a member of the AMPK family, is activated by
glucose starvation through Akt, and acts as a major factor in
Akt-dependent cancer cell survival and migration via stim-
ulation of MT1-MMPs in vitro (12). Carcinoembryonic anti-
gen (CEA) participates in cellular differentiation and tumor
invasion (13). S100A4, also known as metastasin or calvas-
culin, is overexpressed in primary colorectal cancers, compared
with normal mucosa, and liver metastases (10). 
In this study, we determined the association of known genet-
ic changes of tumorigenesis in sporadic colorectal cancers
with tumor growth and invasion. We additionally analyze
the mRNA expression of invasion-associated genes, specifi-
cally, MMP2, MMP9, VEGFA, ARK5, CEA, and S100A4,
in 92 tissue samples and 12 cell lines.
MATERIALS AND METHODS
Tumor samples and DNA/RNA preparation
Fresh colorectal tissues and lymphocytes from 92 patients
were obtained between 2006 and 2007 at the Asan Medical
Center (Seoul, Korea). Of the 92 colon cancers, 32 were locat-
ed in the right colon, 30 in the left colon, and 30 in the rec-
tum. Tumor tissues and samples of the corresponding normal
mucosa at least 5 cm from the tumor border were cryopre-
served in liquid nitrogen immediately after acquisition. All
neoplastic tissues were confirmed by histologic identification,
and peripheral blood lymphocytes from patients were obtain-
ed for genetic and molecular analyses. All patient samples
were acquired with informed consent, and the study was con-
ducted with the approval of the Institutional Review Board
for Human Genetic and Genomic Research, in accordance
with the declaration of Helsinki. Twelve human colorectal
carcinoma cell lines, specifically, RKO and SW48, HT29,
SW480, and HCT116 from the American Type Culture Col-
lection (Rockville, MD, USA), KM12c, WiDr, DLD1, HCT-
15, Caco2, and LoVo from the Korean Cell Line Bank (Seoul,
Korea), and AMC5 established in our laboratory, were main-
tained. HeLa and CCD841 control cell lines were provided
by Yonsei University (Seoul, Korea). Cell lines were main-
tained in their respective media supplemented with 10% fetal
bovine serum and antibiotics, according to standard proto-
cols. DNA was extracted using the standard method and the
corresponding cDNA synthesized by amplification with ran-
dom primers and SuperScript II RT (Invitrogen, Grand Island,
NY, USA).
Genetic alterations associated with colorectal 
tumorigenesis
An automated DHPLC instrument (WAVETM, Transge-
nomic, Omaha, NE, USA) was employed to examine muta-
tions in APC exons 1-14 of genomic DNA from tumor tis-
sues and cell lines. We used the protein truncation test (PTT)
to identify the translation-terminating mutation in exon 15
(14). ‘Hot spots’ or possible pathogenic mutation sites were
determined for other genes, specifically, RAS codons 12 and
13 and RAF codon 600 (17). MSI status was evaluated on
the basis of the Bethesda panel (BAT25, BAT26, D5S346,
D2S123, and D17S250). To assay for hMLH1 methylation,
we analyzed the 3′ small region close to the transcription start
site, which is invariably associated with absence of hMLH1
expression in colorectal tumors, in addition to the 5′pro-
moter region (15).
Immunohistochemistry and immunofluorescence
Paraffin-embedded tissue cores of carcinomas were used for
tissue microarray construction, and arrayed onto recipient
paraffin blocks with a precision instrument (Beecher Instru-
ment, Sun Prairie, WI, USA). Tissue array blocks contain-
ing core cylinders were subjected to immune staining based
on the labeled streptavidin-biotin method using the DAKO
LSAB
� kit (DAKO, Carpinteria, CA, USA). Protein mark-
ers included Wnt-activated alterations (b-catenin, Axin2,
GSK3b), mismatch repair proteins (MLH1, MSH2), MEK,
CEA, and p53 (antibody details available on request). For
all samples displaying negative immune staining on a tissue
microarray, whole tissue sections were repeatedly assayed. Neg-
ative staining was mainly classified into two groups, specifi-
cally, no to weak staining (≤10%) and no staining. The for-
mer group included GSK3b, MLH1 and MSH2 (nuclear),
and p53, and the latter contained Axin2 and MEK. For b-
catenin and CEA, cytoplasmic and no or apicoluminal stain-
ing were interpreted as negative, whereas nuclear and diffuse
cytoplasmic staining were defined as positive, respectively.
For immunofluorescence, cells cultured on 8-well chamber
slides (Lab-Tek, Nunc, Rochester, NY, USA) were treated
with primary antibodies, followed by FITC-conjugated sec-
ondary antibodies (goat anti-mouse, Sigma, St. Louis, MO,
354 S.A. Roh, E.Y. Choi, D.H. Cho, et al.USA; goat anti-rabbit, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). Images were collected using a laser scanning
confocal microscope (Leica Microsystems GmbH, Wetzlar,
Germany).
Real-time reverse transcription-polymerase chain reaction
(RT-PCR)
ARK5, CEA, MMP-2, MMP-9, S100A4, and VEGFA
gene copy numbers were analyzed by RT-PCR (primer sequ-
ences available on request). Quantitative real-time RT-PCR
was performed on a LightCycler (Roche, Mannheim, Ger-
many) using the Fast Start kit, according to the manufactur-
er’s instructions. Upregulation was determined when differ-
ential expression of mRNA (tumor/normal epithelium) was
over one-fold. 
Gelatin zymography assay
MMP-2 and MMP-9 activities in culture media were ex-
amined on a gelatin zymography. Concentrated conditioned
media (×10) mixed with sample buffer were electrophores-
ed on a 10% sodium dodecyl sulfate-polyacrylamide gel with
0.1% gelatin (Invitrogen, Grand Island, NY, USA) incorpo-
rated as a substrate for gelatinolytic proteases under non-reduc-
ing conditions at 125 V for 2 hr. The gel was incubated at
37℃ for 16 hr in fresh developing buffer, and stained with
0.5% Coomassie brilliant blue R-250 (Bio-Rad, Hercules,
CA, USA). Bands on the gels were measured using densito-
metry analyses (Bio-Rad).
Invasion and migration assay
Twenty-four well Transwells containing 8 mm pores coated
with Matrigel (50 mL/well; BD Biosciences, Palo Alto, CA,
USA) were used to assess cell invasion. Cells (5×105) in serum-
free medium were seeded in duplicate in the upper chamber
and 3T3 fibroblast-conditioned medium as a chemoattractant
was placed in lower wells. Chambers were incubated at 37℃
in 5% CO2 for 24 hr. Invading cells on the lower surface of
the filter were fixed with ice-cold methanol, and stained using
0.5% crystal violet. For the migration assay, cells were incu-
bated in chambers without Matrigel to examine migration
potentials using a similar procedure as the invasion assay.
Statistical analysis
Genetic and molecular alterations as well as invasion-asso-
ciated gene expression were compared with each other or var-
ious clinicopathologic parameters by cross-table analysis using
Fisher’s exact or Pearson’s chi-square-tests, depending on sta-
tistical validity. The correlations between differential mRNA
expressions of invasion-associated genes were assessed using the
significance of the product-moment correlation test. Numeri-
cal variables or differential gene expression of independent
groups were examined using the unpaired Student’s t-test
or analysis of variance (ANOVA) with least-squares deviation
(LSD) verification. The significance level was adjusted at 5%
for each analysis, and all calculations were performed using
SPSS software (ver.13, SPSS Inc., Chicago, IL, USA).
RESULTS
Genetic changes in colorectal cancer tissues and cell lines
Alterations in p53 were the most frequent (71%), follow-
ed by Wnt-activated alterations (48%), and MMR defects
(21%). APC or Wnt-activated alterations occurred in 66%
(59/90 patients), whereas MMR defects or RAF-mediated
alterations were identified in 47% (42/90 patients). The cro-
ssover rate between APC/Wnt-activated and MMR/RAF-
mediated alterations was 26%. Colorectal tumorigenesis path-
ways involving distinct genetic and molecular changes were
compared in terms of biological features (Table 1). 
APC mutations did not differ among various tumor loca-
tions, while MMR defects were predominantly identified in
right colon cancers (P=0.002). RAF V600E mutation was
exclusively found right colon cancers (P=0.02), while RAS
G12D mutation was significantly less frequent in rectal can-
cers (P=0.02). The crossover pathways between APC/Wnt-
activated and MMR/RAF-mediated alterations were signifi-
cantly more common in right or left colon cancers than rec-
tal cancers (P=0.018). In terms of biological characteristics,
MMR defects were three times more frequent in poorly dif-
ferentiated or mucinous adenocarcinomas compared to well
or moderately differentiated adenocarcinomas (P=0.027).
Wnt-activated and p53 alterations were identified in all 12
colorectal cancer cell lines by immunofluorescence analysis.
Crossovers between APC/Wnt-activated and MMR/RAF-
mediated alterations were observed in nine of the cell lines,
i.e., DLD1, HCT15, HCT116, HT29, KM12c, LoVo, RKO,
SW48, and WiDr. 
mRNA expressions of invasion-associated genes in 
colorectal cancer tissues and cell lines
Differential mRNA expressions (tumor/normal epithelium)
of four invasion-associated genes, i.e., ARK5, MMP2, MMP9,
and S100A4 were closely associated among them. MMP2 was
closely related to those of MMP9 (P<0.001). ARK5 expres-
sions were closely associated with MMP2, MMP9, and S100-
A4 expressions, whereas S100A4 expressions were addition-
ally associated with VEGFA. Otherwise, CEA expressions did
not correlated with other invasion-associated genes. Enhanced
differential mRNA expressions of several invasion-associated
genes were related to tumor progression and invasion (Table 2).
Enhanced MMP2 expressions were more frequently identi-
Biological Characterization of Colorectal Cancers 355fied in colon cancers than rectal cancers (P=0.046). Advanced
cancers were associated with enhanced CEA expressions and
poorly differentiated and mucinous cancers with enhanced
VEGFA expressions (P=0.034 and 0.042, respectively). 
Enhanced mRNA expressions of most invasion-associat-
ed genes were relatively evident in AMC5 (ARK5, MMP2,
MMP9, and VEGFA) and SW48 (ARK5, CEA, MMP2,
MMP9, and VEGFA) cell lines (Fig. 1). KM12c and SW480
cell lines displayed increased S100A4 mRNA expression,
whereas WiDr cell line did VEGFA mRNA overexpression.
mRNA expressions of invasion-associated genes in 
relation to genetic alterations 
In sporadic colorectal cancers, differential mRNA expres-
sions of invasion-associated genes were examined to corre-
late with genetic alterations (Table 3). Enhanced expression
of ARK5 was more frequent in tumors with RAF-mediated
alterations or crossover pathways carrying APC/Wnt-acti-
vated and MMR/RAF-mediated alterations than those with-
out them (P=0.001 and 0.003, respectively). MMP9 expres-
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*Location: R, ceceum to splenic flexure of transverse colon, L, splenic flexure of transverse colon to sigmoid colon, P, rectum; AJCC stage, cancer stag-
ing according to the American Joint Committee on Cancer (6th ed., 2001); Differentiation, WD, MD, PD, and muc, well-, moderately-, poorly-differenti-
ated, and mucinous; LVN invasion, lymphovascular or neural invasion of tumor cells (Am J Surg Pathol 2003; 27(5);563-70); 
�
Includes RAF V600E muta-
tion, RAS codons 12 and 13 mutations, and MEK-suppressed alterations; 
�
Both APC/Wnt-activated and MMR/RAF-mediated alterations.
MMR, mismatch repair; APC, adenomatous polyposis coli.
Genetic 
alterations
Biological features of tumors*, % (P value, significant)
Altered/all cases 
(%) Location,
R, L, P
AJCC stage, 
I+II, III+IV
Differentiation,
WD+MD, PD+muc
LVN invasion,
No, yes
APC mutations 32/92 (35) 38/23/43 39/30 35/36 37/30
Wnt-activated 43/90 (48) 47/43/53 49/46 49/36 48/47
b-catenin, nuclear 27/30/37 28/36 32/18 29/36
GSK-3b-suppressed 20/13/21 24/10 18/27 23/7
Axin2-suppressed 12/21/11 19/9 15/10 15/12
MMR defects 19/90 (21) 40/17/3 (0.002) 27/10 17/50 (0.027) 18/23
MLH1/MSH2-suppressed 30/7/3 (0.005) 17/8 10/40 (0.027) 13/14
MSI-H 16/7/3 (0.001) 18/6 8/50 (0.003) 8/3
MLH1 5′ -or 3′ -methylation 23/17/0 (0.029) 17/8 11/27 7/5
RAF-mediated
� 30/90 (33) 38/47/13 (0.017) 31/35 32/36 36/27
RAF mutation 13/0/0 (0.02) 2/8 4/9 3/7
RAS mutations 25/37/7 (0.02) 23/23 24/18 26/18
MEK-suppressed 0/14/7 8/5 7/9 8/4
p53 64/90 (71) 72/76/67 75/68 73/64 69/77
Crossover
� 24/90 (26) 38/33/7 (0.018) 31/22 25/36 16/7
Table 1. Genetic changes associated with biological features in sporadic colorectal cancers
*, mRNA expression of tumor/mRNA expression of normal epithelium, >1; Location: R, cecum to splenic flexure of transverse colon, L, splenic flexure
of transverse colon to sigmoid colon, P, rectum; AJCC stage, cancer staging according to the American Joint Committee on Cancer (6th ed., 2001);
Differentiation, WD, MD, PD, and muc, well-, moderately-, poorly-differentiated, and mucinous; LVN invasion, lymphovascular or neural invasion of
tumor cells. 
CEA, carcinoembryonic antigen; MMP, matrix metalloproteinases; VEGFA, vascular endothelial growth factor. 
Invasion-
associated genes
Cases with enhanced differential mRNA expression*, (%; P value, significant)
Location, R, L, P AJCC stage, I+II, III+IV
Differentiation,
WD+MD, PD+muc
LVN invasion, No, yes
ARK5 14/32(44), 13/30(43), 8/30(27) 17/52(33), 18/40(45) 31/81(38), 4/11(36) 22/62(36), 13/30(43)
CEA 8/32(25), 14/30(47), 11/30(37) 14/52(27), 19/40(48) 31/81(38), 2/11(18) 21/62(34), 12/30(40)
(P=0.034)
MMP2 15/32(47), 14/30(47), 6/30(20)  22/52(42), 13/40(33) 31/81(38), 4/11(36) 21/62(34), 14/30(47)
(P=0.046)
MMP9 18/32(56), 15/30(50), 9/30(30) 24/52(46), 18/40(45) 37/81(46), 5/11(46) 25/62(40), 17/30(57)
S100A4 15/32(47), 11/30(37), 8/30(27) 17/52(33), 17/40(43) 30/81(37), 4/11(36) 21/62(34), 13/30(43)
VEGFA 18/32(56), 15/30(50), 16/30(53) 28/52(54), 21/40(53) 40/81(49), 9/11(82) 34/62(55), 15/30(50)
(P=0.042)
Table 2. mRNA expression of invasion-related genes in association biological features in sporadic colorectal cancerssion tended to be increased in tumors with no p53 alterations
(P=0.052). However, no significant association was identified
in the limited number of colorectal cancer cell lines.
Invasion and migration assay in colorectal cancer cell lines
Activities of MMP-2 and MMP-9 were assayed using quan-
titative zymography (Fig. 2). Both active MMP-2 and active
MMP-9 (62 and 82 kDa, respectively) were identified in all
colorectal cancer cell lines except Caco2 and WiDr. Invasion
of tumor cell lines was examined using a modified Boyden
chamber (Transwell coated with Matrigel) (Fig. 3). Invasion
of tumor cells was significantly greater in AMC5 and SW48
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Fig. 1. mRNA expressions (tumor/normal epithelium) of invasion-associated genes (ARK5, CEA, MMP2, MMP9, S100A4, and VEGFA) in
12 colorectal cell lines. Enhanced expressions were relatively evident in AMC5 (ARK5, MMP2, MMP9, and VEGFA) and SW48 (ARK5,
CEA, MMP2, MMP9, and VEGFA) cell lines. Tumor cDNA quantities were normalized in terms of the respective GADPH content.
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*, mRNA expression of tumor/mRNA expression of normal epithelium, >1; 
�
, Both APC/Wnt-activated and MMR defects/RAF-mediated alterations.
CEA, carcinoembryonic antigen; MMP, matrix metalloproteinase; VEGFA, vascular endothelial growth factor; APC, adenomatous polyposis coli.
Genetic alterations 
no, yes
Cases with enhanced mRNA expression*, (%; P value, significant or trend)
ARK5 CEA MMP2 MMP9 S100A4 VEGFA
APC mutations 25/60 (42),  24/60 (40),  22/60 (37),  29/60 (48),  19/60 (32),  32/60 (53), 
10/32 (31) 9/32 (28) 13/32 (41) 13/32 (41) 15/32 (47) 17/32 (53)
Wnt-activated 20/47 (43),  18/47 (38),  18/47 (38),  21/47 (45),  18/47 (38),  26/47 (55), 
14/43 (33) 14/43 (33) 16/43 (37) 20/43 (47) 16/43 (37) 22/43 (51)
MMR defects 27/74 (34),  25/74 (34),  27/74 (36),  32/74 (43),  25/74 (34),  36/74 (49), 
8/18 (44) 6/18 (33) 8/18 (44) 9/18 (50) 7/18 (39) 12/18 (67)
RAF-mediated 17/59 (29),  21/59 (36),  20/59 (34),  26/59 (44),  21/59 (36),  31/59 (53), 
19/33 (58) (P=0.01) 12/33 (36) 16/33 (48) 17/33 (51) 13/33 (39) 17/33 (52)
p53 10/26 (38),  10/26 (38),  13/26 (50),  16/26 (62),  11/26 (42),  15/25 (58), 
23/63 (37) 22/63 (35) 22/63 (35) 25/63 (40) (P=0.052) 22/63 (35) 33/63 (52)
Crossover
� 18/55 (33),  18/55 (33),  20/55 (36),  27/55 (45),  19/55 (35),  29/55 (53), 
21/37 (57) (P=0.03) 13/37 (35) 16/37 (44) 18/37 (49) 16/37 (43) 21/37 (57)
Table 3. Differential mRNA expression of invasion-associated genes associated with genetic alterations in sporadic colorectal cancers
Fig. 2. Gelatinolytic matrix metalloproteinase (MMP) activity in col-
orectal cancer cell lines detected by quantitative zymography.
Molecular markers indicate active MMP-2, proMMP-2, active MMP-
9, and proMMP-9 as 62 kDa, 72 kDa, 82 kDa, and 92 kDa, respec-
tively. 
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62cell lines, compared to Caco2, RKO and WiDr (P=0.001-
0.004). We additionally assessed in vitro migration using
the Transwell migration assay. While all cell lines generally
exhibited remarkably reduced migration compared with con-
trol 3T3, those displaying significant invasion generally main-
tained migratory activity as well (data not shown).
DISCUSSION
Previous investigations have disclosed various molecular
changes in sporadic colorectal cancers, with APC, MMR, Wnt-
activated, RAF-mediated, cell biology-associated, and p53
alterations accounting for approximately 80% of all occur-
rences (1). In our study, APC/Wnt-activated and MMR/RAF-
mediated alterations constituted the major pathways of col-
orectal tumorigenesis (observed in 66% and 47% of patients,
respectively). Alterations in p53 occurred in more than two-
thirds of the patients in our study. Overexpression of mutant
p53 has been reported in 5% to 32% of colorectal adenomas
and 45% to 67% of carcinomas (16). In addition, Wnt-acti-
vated and p53 alterations were identified in all 12 colorectal
cancer cell lines.
In our experiments, MMR defects were closely associated
with right colon, poorly differentiated and mucinous cancers.
Several investigators have reported correlations of right colon
and less differentiated tumors with MMR defects in sporadic
and hereditary colorectal cancer (17, 18). In our study, RAF
mutation was exclusively identified in right colon cancer, while
RAS mutation was significantly less in rectal cancer compar-
ed with colon cancer, possibly explaining unidentified differ-
ences of tumorigenesis between left colon and rectal cancers.
Contrarily to our finding, one recent study demonstrated left
colon cancer as a significant factor for the absence of RAS-sig-
naling alteration (19). Our precedent study recognized rec-
tal cancer as an attenuated phenotype of left colon cancer, with
similarities in MMR defects, RAF-mediated and p53 alter-
ations (20). Additionally, complex tumorigenesis accompa-
nying the crossover between APC/Wnt and MMR/RAF alter-
ations was more frequent for colon cancers than rectal cancers.
In this particular context, MMR defects may trigger tumori-
genesis by targeting transcriptional regulation genes, includ-
ing Wnt and RAF signaling pathways. 
We examined the mRNA expression of six invasion-asso-
ciated genes: MMP2, MMP9, VEGF, ARK5, S100A4, and
CEA. Most of these genes exhibited correlated expression
among them, indicating synergistic interactions in vivo. Over-
expression of MMPs leads to the degradation of ECM, an
essential step for tumor invasion and metastasis (8). In human
colorectal adenocarcinomas patients, MMP9 mRNA and plas-
ma protein levels also increased, compared with normal indi-
viduals (21). Our results disclose a close correlation of MMP2
and MMP9 mRNA expressions in colon cancers. Previous
investigations demonstrate that MMP-2 and MMP-9 increase
in colorectal cancers with infiltrative growth, poor differenti-
ation, and liver metastasis (22, 23). Our finding, shown signifi-
cant upregulation of MMP2 mRNA in colon cancers compar-
ed with rectal cancers, appears to be further verified in terms
of associated molecular changes using accumulative cases. Until
now, several studies have not presented any difference of MMP2
activity between colon and rectal cancers (24).
Cancer cell-derived VEGF exerts pleiotropic effects on pre-
existing endothelial cells and tumor neovascularization (25).
During this angiogenesis switch, VEGF regulates endothelial
cell proliferation, migration, invasion, survival, and branching
morphogenesis. VEGF-A and VEGF-B function early in tumor
development at the stage of adenoma formation, while VEGF-
C plays a role in advanced disease, such as metastatic spread
of colorectal cancers. In our study, upregulation of VEGFA
transcription was correlated with poorly differentiated or muci-
nous colorectal cancers. Similarly, expression of the major VEGF
receptor, pVEGFR2/KDR, in cancer cells was associated with
large tumors and poor differentiation (25). Hypoxia commonly
develops within solid tumors as one of the most potent stim-
uli of VEGF expression (26).
AMP-activated protein kinases (AMPKs) are a class of ser-
ine/threonine protein kinases activated by an increase in the
intracellular AMP concentration. ARK5, an AMPK catalytic
subunit family member, plays diverse roles in human malig-
nancy, i.e., tumorigenesis, proliferation, survival, invasion,
and metastasis (27). Overexpression of ARK5 results in MMP-
2 and MMP-9 activation through MT1-MMP overproduc-
tion in some cancer cell lines (27). This finding may explain
the concurrent differential mRNA expressions of MMP2 and
MMP9 in our study, suggesting a relationship between inva-
siveness and coexpression of ARK5 and MMPs. In our study,
ARK5 mRNA expression was associated with RAF-mediat-
ed and crossover pathways, possibly signifying invasive alter-
ations. Recent reports show that RAF is a novel indicator of
progression and aggressiveness in papillary thyroid cancer (28).
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Fig. 3. Tumor cell invasion and migration were examined on a mod-
ified Boyden chamber (Transwell coated with Matrigel for invasion).
Mean number (±SEM) of invading cells of five fields of triplicate
wells from three independent experiments. AMC5 and SW48 vs.
Caco2, RKO, and WiDr, P<0.001-0.004.
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0While glucose transport dependent on AMPK is mediated
via ERK, the molecular function of ARK5 in the RAF path-
way remains to be verified. S100A4, a direct b-catenin/TCF
target, induces migration and invasion in vitro and metasta-
sis in vivo, and is thereby applicable as a prognostic indica-
tor in metastatic colorectal cancers (29). However, we did not
observe any association of S100A4 upregulation with tumor
stage, histologic differentiation, and lymphovascular invasion.
CEA is a known metastatic potentiator in colorectal cancer,
which facilitates adhesion and metastasis (13). In our exper-
iments, advanced tumor was associated with upregulation
of CEA, consistent with previous finding (30).
Among the 12 colorectal cancer cell lines examined, AMC5
and SW48 displayed overexpression of invasion-associated
genes most frequently, specifically, ARK5, MMP2, MMP9,
and VEGFA in AMC5, and CEA in addition to these genes
in SW48. Additionally, the two cell lines exhibited active
MMP-2 and MMP-9 expressions, known to be exclusively
found in metastatic tissues (22, 23). These cell lines conse-
quently exhibited the greatest invasion and migration activ-
ities on a Boyden chamber assay. On the other hand, KM12c
and SW480 showed S100A4 upregulation with moderate
invasion and migration. The biological aggressiveness data
obtained support a strong correlation between the invasive
behavior of tumor cells in vitro and in vivo, thus validating
this assay as an objective measure of invasive potential (8). The
six invasion-associated genes in this study may therefore be
employed as a set of predictive markers for screening aggres-
sive colorectal cancers, following verification in the clinical
setting.
Conclusively, sporadic colorectal cancers undergo diverse
molecular and genetic changes during tumorigenesis, includ-
ing canonical and crossover pathways, namely, APC-Wnt
alterations, MMR-RAF alterations, and crossover between
the two. Specific pathways are closely associated with char-
acteristic tumor growth and invasion, for example, RAF-medi-
ated and crossover alterations with colon cancers and ARK5A
overexpression related to other invasion-associated molecules,
possibly employed as a panel of predictive markers.
REFERENCES
1. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic
significance of K-ras, p53, and APC mutations in colorectal carci-
noma. Gut 2005; 54: 1283-6. 
2. Senda T, Iizuka-Kogo A, Onouchi T, Shimomura A. Adenomatous
polyposis coli (APC) plays multiple roles in the intestinal and col-
orectal epithelia. Med Mol Morphol 2007; 40: 68-81. 
3. Dong X, Seelan RS, Qian C, Mai M, Liu W. Genomic structure, chro-
mosome mapping and expression analysis of the human AXIN2 gene.
Cytogenet Cell Genet 2001; 93: 26-8. 
4. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh
MD, Barker MA, Arnold S, McGivern A, Matsubara N, Tanaka N,
Higuchi T, Young J, Jass JR, Leggett BA. BRAF mutation is associ-
ated with DNA methylation in serrated polyps and cancers of the col-
orectum. Gut 2004; 53: 1137-44. 
5. Salahshor S, Kressner U, Pa^hlman L, Glimelius B, Lindmark G, Lind-
blom A. Colorectal cancer with and without microsatellite instabili-
ty involves different genes. Genes Chromosomes Cancer 1999; 26:
247-52. 
6. Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic
R, George J, Goldblatt J, Walpole I, Robin SA, Borten MM, Stitz R,
Searle J, McKeone D, Fraser L, Purdie DR, Podger K, Price R, But-
tenshaw R, Walsh MD, Barker M, Leggett BA, Jass JR. Features of
colorectal cancers with high-level microsatellite instability occurring
in familial and sporadic settings: parallel pathways of tumorigenesis.
Am J Pathol 2001; 159: 2107-16. 
7. Vinodhkumar R, Song YS, Ravikumar V, Ramakrishnan G, Devaki
T. Depsipeptide a histone deacetylase inhibitor down regulates levels
of matrix metalloproteinases 2 and 9 mRNA and protein expressions
in lung cancer cells (A549). Chem Biol Interact 2007; 165: 220-9. 
8. Cheung LW, Leung PC, Wong AS. Gonadotropin-releasing hormone
promotes ovarian cancer cell invasiveness through c-Jun NH2-termi-
nal kinase-mediated activation of matrix metalloproteinase (MMP)-
2 and MMP-9. Cancer Res 2006; 66: 10902-10.
9. Collins HM, Morris TM, Watson SA. Spectrum of matrix metallo-
proteinase expression in primary and metastatic colon cancer: rela-
tionship to the tissue inhibitors of metalloproteinases and membrane
type-1-matrix metalloproteinase. Br J Cancer 2001; 84: 1664-70.
10. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regula-
tion of angiogenesis via vascular endothelial growth factor recep-
tors. Cancer Res 2000; 60: 203-12. 
11. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA,
Robinson BA, Fox SB. The angiogenic switch for vascular endothe-
lial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in
the adenoma-carcinoma sequence during colorectal cancer progres-
sion. J Pathol 2003; 200: 183-94. 
12. Kusakai G, Suzuki A, Ogura T, Miyamoto S, Ochiai A, Kaminishi
M, Esumi H. ARK5 expression in colorectal cancer and its implica-
tions for tumor progression. Am J Pathol 2004; 164: 987-95. 
13. Obrink B. CEA adhesion molecules: multifunctional proteins with
signal regulatory properties. Curr Opin Cell Biol 1997; 9: 616-26.
14. Miyoshi Y, Ando H, Nagase H, Nishisho I, Horii A, Miki Y, Mori T,
Utsunomiya J, Baba S, Petersen G, Hamilton SR, Kinzler KW, Vogel-
stein B, Nakamura Y. Germ-line mutations of the APC gene in 53
familial adenomatous polyposis patients. Proc Natl Acad Sci USA
1992; 89: 4452-6. 
15. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M,
Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, Jass
JR, Tanaka N, Matsubara N. Colorectal cancer with mutation in
BRAF, KRAS, and wild-type with respect to both oncogenes show-
ing different patterns of DNA methylation. J Clin Oncol 2004; 22:
4584-94.
16. Einspahr JG, Martinez ME, Jiang R, Hsu CH, Rashid A, Bhattachar-
rya AK, Ahnen DJ, Jacobs ET, Houlihan PS, Webb CR, Alberts DS,
Hamilton SR. Associations of ki-ras proto-oncogene mutation and
p53 gene overexpression in sporadic colorectal adenomas with demo-
Biological Characterization of Colorectal Cancers 359graphic and clinicopathologic characteristics. Cancer Epidemiol
Biomarkers Prev 2006; 15: 1443-50. 
17. Jover R, Paya@ A, Alenda C, Poveda MJ, Peiro@ G, Aranda FI, Pe@rez-
Mateo M. Defective mismatch-repair colorectal cancer: clinicopatho-
logic characteristics and usefulness of immunohistochemical analy-
sis for diagnosis. Am J Clin Pathol 2004; 122: 389-94. 
18. Kim JC, Lee KH, Ka IH, Koo KH, Roh SA, Kim HC, Yu CS, Kim
TW, Chang HM, Gong GY, Kim JS. Characterization of mutator
phenotype in familial colorectal cancer patients not fulfilling Ams-
terdam criteria. Clin Cancer Res 2004; 10: 6159-68. 
19. Harada K, Hiraoka S, Kato J, Horii J, Fujita H, Sakaguchi K, Shira-
tori Y. Genetic and epigenetic alterations of Ras signalling pathway
in colorectal neoplasia: analysis based on tumour clinicopathologi-
cal features. Br J Cancer 2007; 97: 1425-31. 
20. Kim JC, Cho YK, Roh SA, Yu CS, Gong G, Jang SJ, Kim SY, Kim
YS. Individual tumorigenesis pathways of sporadic colorectal ade-
nocarcinomas are associated with the biological behavior of tumors.
Cancer Sci 2008; 99: 1348-54.
21. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR,
Dano K, Nielsen BS. MMP-9 is differentially expressed in primary
human colorectal adenocarcinomas and their metastases. Mol Can-
cer Res 2006; 4: 293-302. 
22. The@ret N, Musso O, Campion JP, Turlin B, Lore@al O, L’Helgoualc’h
A, Cle@ment B. Overexpression of matrix metalloproteinase-2 and
tissue inhibitor of matrix metalloproteinase-2 in liver from patients
with gastrointestinal adenocarcinoma and no detectable metastasis.
Int J Cancer 1997; 74: 426-32. 
23. Zeng ZS, Guillem JG. Unique activation of matrix metalloproteinase-
9 within human liver metastasis from colorectal cancer. Br J Cancer
1998; 78: 349-53.
24. Chan CC, Menges M, Orzechowski HD, Orendain N, Pistorius G,
Feifel G, Zeitz M, Stallmach A. Increased matrix metalloproteinase
2 concentration and transcript expression in advanced colorectal
carcinomas. Int J Colorectal Dis 2001; 16: 133-40. 
25. Giatromanolaki A, Koukourakis MI, Sivridis E, Chlouverakis G,
Vourvouhaki E, Turley H, Harris AL, Gatter KC. Activated VEGFR2/
KDR pathway in tumour cells and tumour associated vessels of col-
orectal cancer. Eur J Clin Invest 2007; 37: 878-86. 
26. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 inde-
pendent pathways in tumor angiogenesis. Clin Cancer Res 2007; 13:
5670-4.
27. Kusakai G, Suzuki A, Ogura T, Kaminishi M, Esumi H. Strong asso-
ciation of ARK5 with tumor invasion and metastasis. J Exp Clin Can-
cer Res 2004; 23: 263-8. 
28. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic
role, molecular bases, and clinical implications. Endocr Rev 2007;
28: 742-62.
29. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins
SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker
RH. The metastasis-associated gene S100A4 is a novel target of beta-
catenin/T-cell factor signaling in colon cancer. Gastroenterology
2006; 131: 1486-500. 
30. Levy M, Visokai V, Lipska L, Topolcan O. Tumor markers in stag-
ing and prognosis of colorectal carcinoma. Neoplasma 2008; 55:
138-42.
360 S.A. Roh, E.Y. Choi, D.H. Cho, et al.